Clinical trials: Cellular Rejection
Kidney Transplantation, Renal Transplantation
Tolerance by Engaging Antigen During Cellular Homeostasis
Anti-rejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent rejection of the new organ.
- Conditions
- Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient
- Trial name
- TEACH (NCT03504241)
- Testing
- Donor-derived Mesenchymal Stromal Cells, alemtuzumab, belatacept
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplant Infection, Kidney Transplant Rejection
Evaluation of Cell-mediated Immune Response by QuantiFERON Monitor® Assay in Kidney Transplant Recipients
All kidney transplant recipients require immunosuppression, the net level of which is difficult to assess. Current practice in assessing immune reactivity is to monitor levels of some immunosuppressive drugs.
- Trial name
- NCT03488771
- Where
- Croatia
- Volunteers
- 150 people
- Sponsor
- Clinical Hospital Merkur
Graft Failure
Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant
Major Objectives A. To determine whether stable allogeneic hematopoietic engraftment can be safely established in patients who have rejected (<5% T Cell Chimerism) a previous allogeneic hematopoietic stem cell graft by using an…
- Trial name
- NCT00472329
- Testing
- Allogeneic hematopoietic stem cell graft using an allogeneic SCT HLA-Identical or non-identical family donor or unrelated donors, fludarabine, TBI
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Colorado Blood Cancer Institute
Lung Transplant Rejection
Cell-free DNA as a Biomarker After Lung Transplantation
The purpose of this investigation is to determine the association of the fraction of donor-derived cell-free DNA in plasma and lung fluid samples with acute rejection as proven by biopsy in lung transplant recipients.
- Trial name
- NCT04271267
- Testing
- No Intervention
- Volunteers
- 126 people
- Sponsor
- Duke University
Transplant Rejection, Transplant Kidney
Study of the Plasma and Urinary cfDNA of in Kidney Transplant Patients
It has been shown that the amount of circulating donor-cell-free DNA increases in patients with transplant rejection. Quantification of single nucleotide polymorphisms (SNPs) present in circulating donor DNA currently allows for…
- Trial name
- PLAKID-TRANSP (NCT06910527)
- Where
- France
- Volunteers
- 250 people
- Sponsor
- Poulet Geoffroy
Heart Transplantation
Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Prevent Rejection in Heart Transplant Children
The investigators developed a protocol to isolate Treg cells from thymic tissue (thyTreg) discarded in pediatric cardiac surgeries.
- Trial name
- THYTECH (NCT04924491)
- Testing
- Autologous thyTreg
- Where
- Spain
- Volunteers
- 11 people
- Sponsor
- Rafael Correa-Rocha
Non Hodgkin's Lymphoma, Hodgkin Disease
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant
The proposed study is based on our observation of paradoxical tumor regression after rejection of the donor graft in conjunction with the results of our murine experiments.
- Conditions
- Non Hodgkin's Lymphoma, Hodgkin Disease, Multiple Myeloma
- Trial name
- RLI (NCT00909948)
- Testing
- Fludarabine and total body irradiation, Total body irradiation
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Massachusetts General Hospital
Renal Transplant
B Cell Lymphocyte in Humoral Rejection and Alloimmunisation
This study aims to better characterise B cell phenotype and functional abnormalities in kidney transplant patients producing donor specific antibody (DSA) and in those with chronic antibody mediated rejection (cAMR) and to search…
- Trial name
- BHL (NCT03016455)
- Testing
- Presence of DSA w/ cAMR, Presence of DSA w/o cAMR, No DSA No cAMR
- Where
- 13 sites in France
- Volunteers
- 116 people
- Sponsor
- University Hospital, Brest
Acute Cellular Graft Rejection, Liver Transplant Rejection
Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects
Our hypothesis is that budesonide will provide effective hepatic ISP that will replace prednisone and allow lower systemic drug levels of FK, thus reducing the steroid- and calcineurin-associated complications often observed in…
- Trial name
- BILT (NCT03315052)
- Testing
- Budesonide, Tacrolimus（FK506）, Mycophenolate Mofetil
- Sponsor
- Montefiore Medical Center
Acute Leukemia
Safety and Efficacy Study of Umbilical Cord Blood-Drived Mesenchymal Stem Cells to Promote Engraftment of Unrelated Hematopoietic Stem Cell Transplantation
The purpose of this study is to evaluate the safety and efficacy of PROMOSTEM (human umbilical cord blood-derived mesenchymal stem cells) at a dose of 1 and 5x1,000,000 hMSC/kg in subject for the promotion of an engraftment and…
- Trial name
- NCT00823316
- Testing
- Human umbilical cord blood-derived mesenchymal stem cells
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Medipost Co Ltd.
Lung Transplant Failure and Rejection
Assessment of Donor Derived Cell Free DNA and Utility in Lung Transplantation
The use of Allosure to identify and quantify circulating donor-derived cell-free DNA to quantitate allograft injury in the early post-transplant period and determine its relationship to allograft failure.
- Trial name
- NCT04318587
- Testing
- Allosure
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Pablo Sanchez
Renal Transplant Rejection
To Elucidate the Effect of Mesenchymal Stem Cells on the T Cell Repertoire of the Kidney Transplant Patients
Despite being a miracle of modern medicine, solid organ transplant recipients are always at risk of rejection, and remain dependent on lifelong immunosuppression.
- Trial name
- NCT02409940
- Testing
- Mesenchymal Stem Cells
- Where
- India
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Renal Transplantation, Mesenchymal Stem Cells
Mesenchymal Stromal Cells in Living Donor Kidney Transplantation
Kidney transplantation is a good treatment option for people with kidney disease. However, there is still much to learn about how to best care for the transplanted kidney and keep it functioning for a long time.
- Trial name
- NCT03478215
- Testing
- Mesenchymal Stromal Stem Cells (MSCs) Infusion
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- The Methodist Hospital Research Institute
Kidney Transplantation
A Safety and Efficacy Study of FCR001 Cell Therapy in Previously Transplanted Living Donor Kidney Recipients
An open-label study to assess the safety, tolerability, and efficacy of FCR001 cell therapy in adult recipients 3-12 months after kidney transplantation from a living donor.
- Trial name
- FREEDOM-2 (NCT01649388)
- Testing
- FCR001
- Where
- 3 sites in United States
- Sponsor
- Talaris Therapeutics Inc.
Renal Transplant Rejection
Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients
This study is being done to investigate the impact of changing immunosuppressive medications from tacrolimus (Prograf®) to sirolimus (Rapamune®) between 6 and 24 months post transplant.
- Trial name
- NCT00866879
- Testing
- Sirolimus, Demographic Data, Medical History, and Donor Data, Blood Draws for Control Group
- Where
- United States
- Volunteers
- 275 people
- Sponsor
- Northwestern University
Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
All individuals who receive a heart transplant are at risk for developing antibody-mediated rejection (AMR). An antibody is a protein produced by the body's immune system when it detects a foreign substance, called an antigen.
- Conditions
- Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant, Left Ventricular Dysfunction, Cardiac Allograft Vasculopathy
- Trial name
- DUET (NCT02013037)
- Testing
- Eculizumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Cedars-Sinai Medical Center
Kidney Transplant Rejection
Cellular Immunotherapy in Recipients of Human Leukocyte Antigen (HLA)-Mismatched, Living Donor Kidney Transplants
The Phase 2 primary objective is to evaluate achievement of persistent mixed chimerism and withdrawal of at least one immunosuppression drug for a minimum of 6 months with no episodes of biopsy-proven acute rejection or…
- Trial name
- NCT03605654
- Testing
- MDR-102, Immunosuppressive Agents
- Sponsor
- Medeor Therapeutics, Inc.
Renal Transplant Rejection, Tolerance
Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor
The purpose of this study is to find out if an investigational treatment will allow kidney transplant recipients to better accept their new kidney and stop immunosuppressive medicines.
- Conditions
- Renal Transplant Rejection, Tolerance, Kidney Transplant
- Trial name
- NCT03707262
- Testing
- Donor CD34+ and CD3+ cells
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Jeffrey Veale, MD
Organ Transplantation
Mesenchymal Stem Cells and Subclinical Rejection
The purpose of the study is to test the safety and feasibility of autologous mesenchymal stem cell therapy in HLA-DR mismatched patients with subclinical rejection and or an increase in IF?TA in the renal biopsy 4 weeks or 6…
- Trial name
- Measure (NCT00734396)
- Testing
- Mesenchymal stem cell infusion
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Leiden University Medical Center
Liver Transplantation (LT), Immuno-suppression
Immune Biomarkers for Predicting Complications After Liver Transplantation
This multicenter prospective observational study will evaluate immune biomarkers in adults undergoing liver transplantation. The study aims to describe how immune markers change before and after transplantation and to assess…
- Conditions
- Liver Transplantation (LT), Immuno-suppression, Biomarkers / Blood, Rejection
- Trial name
- NCT07875595
- Testing
- Immune Biomarker Assessment
- Where
- 3 sites in Argentina
- Volunteers
- 60 people
- Sponsor
- Hospital Italiano de Buenos Aires